Marked efficacy of combined three‐drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome. (18th December 2017)

• Record Type: Journal Article
• Authors: Morimoto, M.; Shimakawa, S.; Hashimoto, T.; Kitaoka, T.; Kyotani, S.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 43:Number 4(2018)
• Page Start: 571
• Page End: 573
• Publication Date: 2017-12-18
• Subjects: anti‐epileptic drug -- Combination Therapy -- dravet syndrome; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12659
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Dravet syndrome (DS) is an intractable epilepsy syndrome. The three‐drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide. Case summary: We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective. What is new and conclusion: It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy. Abstract : In drug therapy for patients with Deavet syndrome, combination therapy of Valproate, Clobazam and Stiripentol is recommended. In this case, combination therapy using Topiramate instead of Clobazam, it was effective for epileptic seizures.